Benitec Biopharma Ltd ADR - Asset Resilience Ratio
Benitec Biopharma Ltd ADR (BNTC) has an Asset Resilience Ratio of 0.12% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Benitec Biopharma Ltd ADR to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2020)
This chart shows how Benitec Biopharma Ltd ADR's Asset Resilience Ratio has changed over time. See how leveraged is Benitec Biopharma Ltd ADR's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Benitec Biopharma Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BNTC stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $63.00K | 0.12% |
| Total Liquid Assets | $63.00K | 0.12% |
Asset Resilience Insights
- Limited Liquidity: Benitec Biopharma Ltd ADR maintains only 0.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Benitec Biopharma Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Benitec Biopharma Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Benitec Biopharma Ltd ADR (2015–2020)
The table below shows the annual Asset Resilience Ratio data for Benitec Biopharma Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-06-30 | 0.01% | $1.00K | $11.74 Million | -0.65pp |
| 2019-06-30 | 0.66% | $126.76K | $19.21 Million | +0.52pp |
| 2018-06-30 | 0.14% | $22.04K | $15.68 Million | -0.30pp |
| 2017-06-30 | 0.44% | $76.84K | $17.42 Million | +0.43pp |
| 2016-06-30 | 0.01% | $1.10K | $14.85 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $19.57 Million | -- |
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more